Our Pipeline
We are programming biology to create optimal therapeutics for the greatest impact on human health.
| Program | Target | Indication | Phase | Collaborations | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Generating | IND Enabling | Phase 1 | Phase 2 | Phase 3 | ||||||||
| Immunology | ||||||||||||
| GB-0895 | TSLP | Severe Asthma |
Phase Phase 3 |
|||||||||
|
Modality: monoclonal antibody How this investigational therapy could help: Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that helps drive airway inflammation and asthma exacerbations. GB-0895 is an investigational antibody that binds and neutralizes TSLP to help reduce downstream inflammatory signaling in severe asthma. It is engineered for an extended half-life and is being studied for twice-yearly subcutaneous dosing, which may offer administration flexibility and convenience if proven safe and effective. GB-0895 is currently being evaluated in Phase 3 clinical studies. |
||||||||||||
| GB-0895 | TSLP | COPD |
Phase Phase 1 |
|||||||||
| GB-7624 | IL-13 | Atopic Dermatitis |
Phase Phase 1 |
|||||||||
| Other mono and combo | Several | Several |
Phase Generating |
|||||||||
| Oncology | ||||||||||||
| GB-5267 | Undisclosed | Advanced Solid Tumors |
Phase IND Enabling |
Collaborations 
50/50
|
||||||||
| Bispecific | Undisclosed | NSCLC |
Phase Generating |
Collaborations
The University of Texas
MD Anderson Cancer Center 50/50 |
||||||||
| GB-4362 | Free MMAE | Various in combo with MMAE ADCs |
Phase IND Enabling |
|||||||||
| Infectious Disease | ||||||||||||
| GB-0669* | SARS-CoV-2 S2 | COVID-19 |
Phase Phase 1 Completed |
|||||||||
| Undisclosed | ||||||||||||
| Amgen |
6 Undisclosed Programs
|
Collaborations 
|
||||||||||
| Novartis |
Multiple Undisclosed Programs
|
Collaborations 
|
||||||||||
|
*Deprioritized for internal development |
||||||||||||
Currently, participation in clinical trials is the only way for patients to gain access to Generate:Biomedicines’ investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.